NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2”) ( HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc.
(“Janssen”).HC2 Announces Pansend Life Sciences Portfolio Company BeneVir Biopharm to be Acquired by Janssen Biotech, Inc. for up to $1.04 Billion
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться